SJNB-JF-IL2

Developed for: neuroblastoma
Investigated by: Baylor College of Medicine · Center for Cell and Gene Therapy, Baylor College of Medicine

today NCT00703222 · Ph 1/2

20082009201020112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1/2	NCT00703222	Jun 2008 → May 2011	neuroblastoma	Baylor College of Medicine	Completed	No outcome recorded

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	SJNB-JF-IL2	“Vaccine components SJNB-JF-IL2 and SJNB-JF-Lptn will each be dosed at 1x10e7 cells/m2” NCT00703222 ↗